



PRIOR AUTHORIZATION REQUEST FORM

EOC ID:

Gleevec or imatinib mesylate

Phone: 800-728-7947

Fax back to: 866-880-4532

The Scott & White Health Plan Pharmacy Department manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. **Please note any information left blank or illegible may delay the review process.**

Patient Name:	Prescriber Name:	
	Supervising Physician:	
Member/Subscriber Number:	Fax:	Phone:
Date of Birth:	Office Contact:	
Group Number:	NPI:	State Lic ID:
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name (if applicable):	

Drug Name and Strength:

Directions / SIG:

Please attach any pertinent medical history or information for this patient that may support approval. Please answer the following questions and sign.

Q1. For what diagnosis is this drug being prescribed (pick one)?

- ☐ Philadelphia chromosome positive Chronic Myeloid Leukemia (CML)
- ☐ Philadelphia chromosome positive Acute Lymphoid Leukemia (ALL)
- ☐ Myelodysplastic Syndrome (MDS)/Myeloproliferative disease (MPD)
- ☐ Aggressive mastocytosis (ASM)
- ☐ Chronic Eosinophilic Leukemia (CEL) and/or Hypereosinophilic Syndrome (HES)
- ☐ Dermatofibrosarcoma Protuberans (DFSP)
- ☐ Gastrointestinal Stromal Tumor (GIST)
- ☐ Other

Q2. Please provide ICD code(s) for diagnosis

Q3. If you selected "other" in question 1, please provide documentation that use is consistent with a category 1 per NCCN compendia or guidelines.

Q4. Is the prescribing physician an Oncologist or Hematologist?

☐ Yes

☐ No



PRIOR AUTHORIZATION REQUEST FORM

EOC ID:

Gleevec or imatinib mesylate

Phone: 800-728-7947

Fax back to: 866-880-4532

The Scott & White Health Plan Pharmacy Department manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. **Please note any information left blank or illegible may delay the review process.**

Patient Name:	Prescriber Name: Supervising Physician:
Q5. If CML, what phase is the disease in? <input type="checkbox"/> Chronic Phase <input type="checkbox"/> Blast Crisis <input type="checkbox"/> Accelerated Phase	
Q6. If CML, is the patient newly diagnosed? <input type="checkbox"/> Yes <input type="checkbox"/> No	
Q7. If CML and not newly diagnosed, has the patient failed interferon-alpha therapy? <input type="checkbox"/> Yes <input type="checkbox"/> No	
Q8. If ALL, is the patient an adult or pediatric patient? <input type="checkbox"/> Adult <input type="checkbox"/> Pediatric	
Q9. If ALL and an adult, does the patient have relapsed or refractory disease? <input type="checkbox"/> Yes <input type="checkbox"/> No	
Q10. If ALL and a pediatric patient, is it a new diagnosis? <input type="checkbox"/> Yes <input type="checkbox"/> No	
Q11. If MDS/MPD, does the patient have PDGFR (platelet-derived growth factor receptor) gene re-arrangements? <input type="checkbox"/> Yes <input type="checkbox"/> No	
Q12. If ASM, does the patient NOT have the D816V c-Kit mutation or is the c-Kit mutational status unknown? <input type="checkbox"/> Yes <input type="checkbox"/> No	
Q13. If HES and/or CEL, is the FIP1L1-PDGFR alpha fusion kinase negative or unknown? <input type="checkbox"/> Yes <input type="checkbox"/> No	
Q14. If DFSP, is the disease unresectable, recurrent and/or metastatic? <input type="checkbox"/> Yes <input type="checkbox"/> No	
Q15. If GIST, is the tumor unresectable and/or metastatic? <input type="checkbox"/> Yes <input type="checkbox"/> No	
Q16. If GIST, if the tumor has been resected, is this being used as adjuvant treatment?	



PRIOR AUTHORIZATION REQUEST FORM

EOC ID:

Gleevec or imatinib mesylate

Phone: 800-728-7947

Fax back to: 866-880-4532

The Scott & White Health Plan Pharmacy Department manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. **Please note any information left blank or illegible may delay the review process.**

Patient Name:	Prescriber Name: Supervising Physician:
<input type="checkbox"/> Yes <input type="checkbox"/> No	
Q17. Who is the ENTITY that will be submitting the CLAIM for the DRUG and seeking reimbursement? <input type="checkbox"/> Pharmacy <input type="checkbox"/> Individual prescriber <input type="checkbox"/> Provider or specialty group <input type="checkbox"/> Facility <input type="checkbox"/> Other (please specify)	
Q18. Provide name and NPI of the billing entity	
Q19. Will the claim for the drug be submitted as a MEDICAL claim or PHARMACY claim (Note: If a pharmacy will be submitting a MEDICAL claim for drug reimbursement, answer MEDICAL)? <input type="checkbox"/> Medical <input type="checkbox"/> Pharmacy	
Q20. Additional Comments	

Prescriber Signature

Date

☐ Expedited/Urgent - By checking this box and signing above, I certify that applying the standard review timeframe may seriously jeopardize the life or health of the enrollee or the enrollee's ability to regain maximum function

Lack of the necessary documentation may result in a medical necessity denial. Requesting providers may speak to a SWHP pharmacist or medical director at 1-800-728-7947 regarding the case to have an opportunity to help impact the decision on a request before coverage has been decided.



PRIOR AUTHORIZATION REQUEST FORM

EOC ID:

Gleevec or imatinib mesylate

Phone: 800-728-7947

Fax back to: 866-880-4532

The Scott & White Health Plan Pharmacy Department manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. **Please note any information left blank or illegible may delay the review process.**

Patient Name:

Prescriber Name:

Supervising Physician:

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document